What Is Interstitial Pneumonia? Causes and Symptoms

Interstitial pneumonia is a group of lung diseases in which inflammation and, often, scarring affect the tissue between the air sacs rather than the air sacs themselves. Unlike the bacterial or viral pneumonia most people think of when they hear the word, interstitial pneumonia tends to develop gradually, causes a persistent dry cough and worsening breathlessness, and frequently has no identifiable infectious trigger at all. The condition comes in several distinct subtypes, each with different causes and outlooks, and the terminology can be confusing because “pneumonia” here refers to lung inflammation in a broad sense rather than a straightforward infection.

How Interstitial Pneumonia Differs From Typical Pneumonia

When most people picture pneumonia, they think of an infection that fills the air sacs (alveoli) with fluid or pus. The illness comes on fast, often with fever and productive cough, and antibiotics or antivirals usually clear it up. Interstitial pneumonia is fundamentally different. The primary damage occurs in the interstitium, the thin scaffold of tissue that supports the air sacs and surrounds the tiny blood vessels where oxygen enters the bloodstream. The 2025 international classification update separates lung disorders into “interstitial” patterns and “alveolar filling” patterns based on where the injury mainly sits, while acknowledging that most cases involve more than one compartment of the lung to some degree.

Because the interstitium is the structural skeleton of the lung, injury there tends to stiffen the tissue rather than simply filling it with fluid. That stiffness makes the lungs harder to expand on each breath, which is why breathlessness during exertion is usually the earliest and most prominent symptom. In many cases the disease is chronic and progressive, whereas conventional pneumonia is typically an acute, time-limited event.

Types of Interstitial Pneumonia

Doctors recognize several patterns of interstitial pneumonia, grouped under the broader umbrella of interstitial lung disease (ILD). Two patterns dominate clinical conversation because they are the most common and their distinction has major implications for prognosis.

Usual interstitial pneumonia (UIP) is the hallmark pattern seen in idiopathic pulmonary fibrosis (IPF), the most feared subtype. UIP features patchy scarring that tends to be worst at the base of the lungs and just beneath the lining of the lung surface. Under a microscope, areas of dense fibrosis sit right next to relatively normal-looking tissue, giving the lung a patchwork appearance. Nonspecific interstitial pneumonia (NSIP) looks different: the inflammation and fibrosis are more uniform throughout the affected regions. The clinical picture of the two can be nearly identical, making the distinction difficult without advanced imaging or biopsy.¹ The effort matters, though, because NSIP carries a substantially better outlook. One study found that five-year survival was about 90% for patients with the fibrosing pattern of NSIP, compared with roughly 43% for those with UIP.²

Other recognized subtypes include cryptogenic organizing pneumonia (COP), in which plugs of inflammatory tissue fill the small airways; desquamative interstitial pneumonia (DIP), most commonly linked to smoking; lymphoid interstitial pneumonia (LIP), frequently associated with autoimmune conditions; and acute interstitial pneumonia (AIP), a rapidly progressive form that resembles acute respiratory distress syndrome. The updated international classification further groups these into fibrotic versus non-fibrotic interstitial patterns, a distinction that shapes treatment decisions because fibrotic disease generally responds differently to therapy and carries a worse prognosis.³

Causes and Triggers

One of the most frustrating things about interstitial pneumonia is that in a large share of cases, no cause is ever found. When that happens, the disease gets the label “idiopathic,” and idiopathic pulmonary fibrosis is the most common example. But many cases do have identifiable triggers, and recognizing them is important because removing the trigger can sometimes slow or even halt the disease.

Autoimmune Diseases

Interstitial lung disease is a well-recognized feature of many systemic autoimmune conditions.⁴ Rheumatoid arthritis, systemic sclerosis (scleroderma), Sjögren syndrome, and inflammatory myopathies like dermatomyositis can all drive interstitial inflammation. In some patients the lung disease appears before the joint or skin symptoms that eventually lead to an autoimmune diagnosis, which means a new diagnosis of interstitial pneumonia should prompt screening for autoimmune markers even when a patient has no obvious joint or skin complaints.

Environmental and Occupational Exposures

Repeated inhalation of certain organic dusts, molds, or chemicals can provoke a delayed allergic reaction in the lung known as hypersensitivity pneumonitis. The classic triggers include bird feathers and droppings, moldy hay, and certain industrial chemicals, though the list of potential culprits is long.⁵ With chronic exposure the lung can develop fibrosis that looks very similar to UIP or NSIP on a CT scan, which is why a thorough occupational and hobby history is essential for any new ILD evaluation. Removing the exposure early, before significant scarring has set in, gives the best chance of recovery.

Medications

More than a hundred drugs have been linked to interstitial lung disease. Chemotherapy agents, certain antibiotics, heart rhythm medications like amiodarone, and some immunosuppressive drugs are among the more common offenders.⁶ Drug-induced ILD can mimic virtually any of the idiopathic interstitial pneumonia patterns, which makes it a diagnosis of exclusion: the timing of drug initiation, the pattern on imaging, and improvement after stopping the drug all factor into the diagnosis.

Infections

While interstitial pneumonia is not an infection in the conventional sense, certain viral infections have been implicated in triggering or accelerating the process. Influenza, for instance, has been documented as a potential initiator of a UIP-like pattern in case reports.⁷ The relationship between viral injury and subsequent fibrosis is an area of active research, especially following the COVID-19 pandemic, which drew wide attention to post-infectious lung scarring.

Genetic Factors

Some families carry mutations that predispose members to interstitial pneumonia. Mutations in more than ten different genes have been identified in families with what researchers call familial interstitial pneumonia (FIP).⁸ These mutations often affect surfactant proteins, telomere maintenance, or immune regulation. If two or more first-degree relatives have been diagnosed with ILD, genetic counseling and testing may be worthwhile, especially for younger patients in whom the disease appears earlier than typical.

Symptoms and How They Progress

Interstitial pneumonia typically announces itself with two cardinal symptoms: a dry, non-productive cough and shortness of breath that worsens with physical activity. In the early stages, breathlessness might only show up during vigorous exercise, making it easy to dismiss as being out of shape or getting older. Over months to years, the threshold drops: climbing a flight of stairs, then walking on flat ground, and eventually resting can all become difficult.

A physical exam finding that strongly points toward interstitial pneumonia is a distinctive sound heard through a stethoscope called Velcro crackles, named because they resemble the sound of pulling apart Velcro fastening. These fine crackling sounds, usually heard at the lung bases toward the end of a breath in, are closely associated with UIP in particular. One study found that every patient with a UIP pattern on high-resolution CT and every patient who ultimately received an IPF diagnosis had Velcro crackles on exam.⁹ Patients with those crackles also more frequently reported cough and breathlessness at the time of diagnosis.

Other symptoms that can develop as the disease progresses include fatigue, unintended weight loss, and finger clubbing, where the fingertips widen and the nails curve downward. Clubbing is not specific to interstitial pneumonia, but when it appears alongside a chronic dry cough and exertional breathlessness, it raises a strong clinical suspicion. In advanced disease, low blood oxygen levels at rest can cause a bluish tinge to the lips and fingernails.

How Interstitial Pneumonia Is Diagnosed

Diagnosis usually starts with a high-resolution CT scan of the chest. The imaging patterns are often distinctive enough to point toward a specific subtype. UIP, for example, classically shows honeycombing (clusters of small cystic spaces) at the lung bases, along with traction bronchiectasis (distorted airways pulled apart by surrounding scar tissue). A study of radiologists evaluating CT scans against the Fleischner Society criteria found moderate to substantial agreement on recognizing UIP patterns, with near-perfect agreement when honeycombing was the feature in question.¹⁰

Pulmonary function tests provide complementary information. The hallmark finding across the idiopathic interstitial pneumonias is a restrictive pattern, meaning the lungs cannot expand fully, combined with a reduced capacity to transfer gases across the lung membrane.¹¹ These tests are also used to track disease progression over time: a drop in lung capacity over six to twelve months is one of the strongest predictors of worsening outcomes.¹²

When imaging and clinical features do not paint a clear picture, a lung biopsy may be needed. The two main approaches are transbronchial lung cryobiopsy (TBLC), where a small probe is passed through the airway to freeze and retrieve a tissue sample, and surgical lung biopsy (SLB), performed through small incisions. European guidelines recommend TBLC as the first-choice biopsy because it can be done as an outpatient procedure with less pain and a shorter recovery. However, a recent systematic review and meta-analysis found that surgical biopsy produced a similar diagnostic yield and comparable short-term mortality, making either approach reasonable depending on the patient and the center’s expertise.¹³

Why Scarring Keeps Getting Worse

In many forms of interstitial pneumonia, especially IPF, the disease is driven by a self-reinforcing cycle of scarring. Injury to the lung lining triggers certain cells called fibroblasts to migrate into the damaged area and begin laying down structural proteins. A growth factor called TGF-β1 pushes these fibroblasts to become myofibroblasts, more aggressive repair cells that deposit large amounts of scar tissue.¹⁴

Here is the insidious part: the scar tissue itself changes the behavior of surrounding fibroblasts, encouraging even more of them to transform into myofibroblasts and produce even more scar. Laboratory studies have shown that when specific scar proteins like elastin accumulate in the tissue, they directly stimulate further fibroblast activation, creating a positive feedback loop.¹⁵ This feedback mechanism helps explain why fibrotic interstitial pneumonia tends to be relentlessly progressive once established, and why treatments that simply reduce inflammation are often not enough to stop it.

Treatment Options

Treatment depends heavily on the specific subtype and cause. When an identifiable trigger exists, such as a drug, an environmental exposure, or an autoimmune disease, addressing the underlying cause is the first priority. For autoimmune-related ILD, immunosuppressive medications can reduce the inflammatory drive behind the lung damage. For hypersensitivity pneumonitis, removing the offending exposure may halt progression.

For idiopathic pulmonary fibrosis specifically, two antifibrotic drugs, pirfenidone and nintedanib, have become the standard of care. Both work by slowing the rate of lung function decline rather than reversing existing scarring. They have been extensively validated across clinical trials, but they come with trade-offs. Gastrointestinal side effects like diarrhea, nausea, and vomiting are common with both drugs, and pirfenidone is additionally associated with photosensitivity and skin rashes.¹² Neither drug is a cure, and for patients with advanced disease, lung transplantation remains the only option that can dramatically change the trajectory.

Supplemental oxygen becomes important when blood oxygen levels fall, particularly during exertion. It does not treat the underlying disease, but it relieves breathlessness and allows patients to maintain a more active lifestyle for longer.

Pulmonary Rehabilitation

One of the most consistently beneficial interventions for interstitial pneumonia is pulmonary rehabilitation, a structured program of supervised exercise, breathing techniques, and education. A Cochrane systematic review found that pulmonary rehabilitation improved the six-minute walk distance by an average of about 40 meters and led to meaningful improvements in quality-of-life scores across multiple validated questionnaires.¹⁶ A more recent meta-analysis reported an even larger average improvement in walking distance and also found that rehabilitation helped reduce the drop in oxygen saturation that patients experience during exertion.¹⁷

The benefits extend beyond physical endurance. A 2025 study measuring patient-reported outcomes found that rehabilitation produced a significant improvement in health-related quality of life, with functional exercise capacity increasing by an average of 48 meters on the six-minute walk test, surpassing the threshold considered clinically meaningful.¹⁸ Despite this evidence, pulmonary rehabilitation remains underutilized for ILD patients, partly because many programs were historically designed around chronic obstructive pulmonary disease and referral pathways for ILD are less well established.

Complications Worth Watching For

Pulmonary hypertension, elevated blood pressure in the arteries supplying the lungs, is one of the most serious complications of interstitial pneumonia. It develops because scarring and inflammation destroy the small blood vessels within the lung, forcing the heart’s right side to pump harder. When it occurs, it worsens functional status and outcomes beyond what the interstitial disease alone would cause.¹⁹ What makes this complication particularly tricky is that the pulmonary vascular disease does not always track with the severity of the underlying lung scarring, so patients can develop dangerous elevations in pulmonary pressure even when their fibrosis appears relatively stable.²⁰

Acute exacerbations represent another feared event. These are episodes of rapid, unexplained worsening over days to weeks, often requiring hospitalization and mechanical ventilation. Several risk factors have been identified for acute exacerbations in IPF, including a resting or exercise oxygen saturation that drops to 88% or below, a decline in lung capacity of 10% or more over a year, and a decline in gas transfer capacity of 15% or more over a year.²¹ Surgery under general anesthesia can also trigger exacerbations, and one study found that higher concentrations of supplemental oxygen during surgery and elevated inflammatory markers were associated with a greater risk of post-operative flare.²²

The Acid Reflux Connection

An underappreciated factor in IPF is gastroesophageal reflux. Abnormal reflux is unusually common in people with pulmonary fibrosis, and there is growing evidence that tiny amounts of stomach contents can be silently aspirated into the lower airways, a process called microaspiration. This chronic low-level chemical injury may contribute to the repeated lung damage that drives fibrosis forward.²³

What makes this link especially interesting is that the damage is not limited to acid. Non-acid components of gastric juice, including digestive enzymes like pepsin, have been detected in the distal airways of IPF patients, particularly during acute exacerbations.²⁴ This means standard acid-suppressing medications may not fully address the problem. Whether aggressive anti-reflux treatment, including surgical options, can actually slow fibrosis progression is still debated, but the hypothesis has generated enough interest that some ILD centers now routinely screen for reflux in their IPF patients. For patients with both conditions, the overlap is worth discussing with a pulmonologist, because treating the reflux may represent a relatively low-risk way to reduce one potential driver of lung injury.